The emerging pipeline for Peripheral Artery Disease (PAD) majorly comprises cell therapies. Ixaka’s REX-001, Hemostemix’s ACP-01, Humacyte’s Human Acellular Vessel (HAV), and Caladrius Bioscience’s Honedra are some of the most highlighted emerging therapies. The emerging therapies are in the late, middle, and early stages of development. Some of these emerging therapies are expected to enter the market in the near future.
DelveInsight’s “Peripheral Artery Disease (PAD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral Artery Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Peripheral Artery Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Peripheral Artery Disease (PAD): An Overview
Peripheral artery disease (also called peripheral arterial disease) is a common circulatory problem in which narrowed arteries reduce blood flow to limbs. In peripheral artery disease (PAD), legs or arms—usually legs—do not receive enough blood flow to keep up with demand. This may cause symptoms, such as leg pain when walking (claudication). Severe Peripheral Artery Disease can further develop into critical limb ischemia, stroke, or heart attack.
Atherosclerotic lower extremity PAD is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects >230 million people worldwide. Lower extremity PAD is characterized by stenosis or occlusion anywhere from the aortoiliac segment to the pedal arteries.
Peripheral Artery Disease (PAD) Market Key Facts
As per DelveInsight’s estimate, in 2021, there were 36,661,000+ cases of PAD in the 7MM. Approximately 55% of cases were reported in the US, compared to about 39% of cases in EU-5; Germany accounted for the highest number among EU-5 countries.
According to Alzamora et al. (2016), the occurrence of Peripheral Artery Disease is higher in men, especially < 65 years.
As per the assessment, Japan accounted for the lowest number of Peripheral Artery Disease cases among the 7MM.
The highest number of cases (approximately 61%) were diagnosed in the US, followed by EU-5 and Japan.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral Artery Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Peripheral Artery Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Peripheral Artery Disease (PAD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Peripheral Artery Disease (PAD) Epidemiology Segmented by-
Total Prevalent Cases of PAD in the 7MM (2019–2032)
Total Diagnosed Prevalent Cases of PAD in the 7MM (2019–2032)
Severity-specific Prevalent Cases of PAD in the 7MM (2019–2032)
Age-specific Prevalent Cases of PAD in the 7MM (2019–2032)
Gender-specific Cases of PAD in the 7MM (2019–2032)
Treatable Cases of PAD in the 7MM (2019–2032)
Peripheral Artery Disease (PAD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Artery Disease market or expected to be launched during the study period. The analysis covers the Peripheral Artery Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Peripheral Artery Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Peripheral Artery Disease Market Will Evolve and Grow by 2032 @
Peripheral Artery Disease (PAD) Therapeutics Analysis
As per DelveInsight’s assessment, with the increasing prevalent cases of peripheral artery disease (PAD) and the expected launch of upcoming therapies, the Peripheral Artery Disease (PAD) market is anticipated to grow at an immense pace in the coming years.
The Leading Companies in the Peripheral Artery Disease (PAD) Therapeutics Market Include:
Merck & Co., Inc
Reven Pharmaceuticals, Inc.)
New Beta Innovation Limited
Ixaka Ltd (formerly known as Rexgenero)
And Many More
Peripheral Artery Disease (PAD) Therapies Covered in the Report Include:
REX-001: Ixaka Ltd (formerly known as Rexgenero)
SAKIGAKE designated Honedra (formerly known as CLBS12): Caladrius Biosciences
Human Acellular Vessel (HAV): Humacyte, Inc.
RJX (Rejuveinix): Reven Pharmaceuticals, Inc.)
YQ23: New Beta Innovation Limited
Temsirolimus: Mercator MedSystems
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Peripheral Artery Disease Competitive Intelligence Analysis
4. Peripheral Artery Disease Market Overview at a Glance
5. Peripheral Artery Disease Disease Background and Overview
6. Peripheral Artery Disease Patient Journey
7. Peripheral Artery Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Peripheral Artery Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Peripheral Artery Disease Unmet Needs
10. Key Endpoints of Peripheral Artery Disease Treatment
11. Peripheral Artery Disease Marketed Products
12. Peripheral Artery Disease Emerging Drugs and Latest Therapeutic Advances
13. Peripheral Artery Disease Seven Major Market Analysis
14. Attribute Analysis
15. Peripheral Artery Disease Market Outlook (In US, EU5, and Japan)
16. Peripheral Artery Disease Access and Reimbursement Overview
17. KOL Views on the Peripheral Artery Disease Market
18. Peripheral Artery Disease Market Drivers
19. Peripheral Artery Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“GM1 Gangliosidosis Market Insights, Epidemiology, and Market Forecast 2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the GM1 Gangliosidosis market size, shares, and trends analysis in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), United Kingdom, and Japan).
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States